<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39387195</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2056-4724</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>BJPsych open</Title><ISOAbbreviation>BJPsych Open</ISOAbbreviation></Journal><ArticleTitle>Projections of anxiety disorder prevalence during and beyond the COVID-19 pandemic in Germany using the illness-death model.</ArticleTitle><Pagination><StartPage>e174</StartPage><MedlinePgn>e174</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1192/bjo.2024.754</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although there is now substantial evidence on the acute impacts of the COVID-19 pandemic on anxiety disorders, the long-term population impact of the pandemic remains largely unexplored.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To quantify a possible longitudinal population-level impact of the pandemic by projecting the prevalence of anxiety disorders through 2030 among men and women aged up to 95 years in Germany under scenarios with varying impacts of the pandemic on the incidence of anxiety disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We used a three-state illness-death model and data from the Global Burden of Disease Study to model historical trends of the prevalence and incidence of anxiety disorders. The German population projections determined the initial values for projections. The COVID-19 incidence rate data informed an additional incidence model, which was parameterised with a wash-in period, delay, wash-out period, incidence increase level and decay constant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">When no additional increase in the incidence during the pandemic waves during 2020-2022 was assumed, it was estimated that 3.86 million women (9.96%) and 2.13 million men (5.40%) would have anxiety disorders in 2030. When increases in incidence following pandemic waves were assumed, the most extreme scenario projected 5.67 million (14.02%) women and 3.30 million (8.14%) men with the mental disorder in 2030.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Any increased incidence during the pandemic resulted in elevated prevalence over the projection period. Projection of anxiety disorder prevalence based on the illness-death model enables simulations with varying assumptions and provides insight for public health planning. These findings should be refined as trend data accumulate and become available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Chisato</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8349-8224</Identifier><AffiliationInfo><Affiliation>Institute of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baune</LastName><ForeName>Bernhard T</ForeName><Initials>BT</Initials><Identifier Source="ORCID">0000-0001-6548-426X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Münster, Münster, Germany; Department of Psychiatry, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia; and Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurth</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7169-2620</Identifier><AffiliationInfo><Affiliation>Institute of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinks</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0961-6592</Identifier><AffiliationInfo><Affiliation>Faculty of Health/School of Medicine, Witten/Herdecke University, Witten, Germany; and Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJPsych Open</MedlineTA><NlmUniqueID>101667931</NlmUniqueID><ISSNLinking>2056-4724</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anxiety disorders</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>21</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>21</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39387195</ArticleId><ArticleId IdType="doi">10.1192/bjo.2024.754</ArticleId><ArticleId IdType="pii">S2056472424007543</ArticleId></ArticleIdList></PubmedData></PubmedArticle>